BIIB — Biogen
Data coverage, completeness and provenance for Biogen in the Stock Market API — Health Care · Drug Manufacturers - General.
Stored price coverage
Source date: 2026-11-19T21:00:00. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-11-19 | 247.1300 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-18 | 251.4100 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-17 | 250.7900 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-16 | 251.6500 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-13 | 253.4000 | USD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/BIIB/prices · Price parameters and adjustment semantics
No archived filings are currently stored for this listing.
Profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Employees: 7,500 · Website: https://www.biogen.com · Profile fields populated: 75%
Data completeness by statement
Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/BIIB/financials.
Financial statement coverage (USD)
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (USD) | 2025-12-31 | 30 | sec_edgar | ||||
| FY2024 (USD) | 2024-12-31 | 30 | sec_edgar | ||||
| FY2023 (USD) | 2023-12-31 | 30 | sec_edgar | ||||
| FY2022 (USD) | 2022-12-31 | 30 | sec_edgar | ||||
| FY2021 (USD) | 2021-12-31 | 31 | sec_edgar |
Get BIIB data via the API
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Company profile
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/BIIB
Financial statements
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/BIIB/financials
Computed ratios
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/BIIB/metrics/summary
News & announcements
Dated press releases and announcements with source links.
GET /api/v1/companies/BIIB/news
Quick start
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/BIIB
Query BIIB programmatically
Free tier — instant API key. Built for AI agents.
Other NASDAQ · Health Care companies covered
Frequently Asked Questions
- What data does the API provide for BIIB?
- Stored coverage for BIIB: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/BIIB; inspect available source metadata for provenance.
- How complete is BIIB's financial data?
- The anchor reporting period (FY2025) has 88.2% of the 17 core statement fields populated. Primary source: sec_edgar.
- What reporting periods are covered for BIIB?
- 5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/BIIB/financials.
- Where does BIIB's data come from?
- Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/BIIB/financials; missing tags do not establish provenance.